Canaccord Genuity Increases Isis Pharmaceuticals Price Target to $45.00 (ISIS)
Research analysts at Canaccord Genuity raised their price target on shares of Isis Pharmaceuticals (NASDAQ:ISIS) from $32.00 to $45.00 in a report released on Thursday, AnalystRatingsNetwork.com reports. The firm currently has a “hold” rating on the stock. Canaccord Genuity’s price target indicates a potential downside of 11.94% from the company’s current price.
Isis Pharmaceuticals (NASDAQ:ISIS) opened at 51.31 on Thursday. Isis Pharmaceuticals has a 52-week low of $13.76 and a 52-week high of $54.90. The stock’s 50-day moving average is $47.69 and its 200-day moving average is $36.82. The company’s market cap is $5.956 billion.
A number of other firms have also recently commented on ISIS. Analysts at Deutsche Bank initiated coverage on shares of Isis Pharmaceuticals in a research note on Wednesday, January 22nd. They set a “buy” rating and a $60.00 price target on the stock. Separately, analysts at Zacks reiterated a “neutral” rating on shares of Isis Pharmaceuticals in a research note on Tuesday, January 21st. They now have a $49.00 price target on the stock. Finally, analysts at Piper Jaffray upgraded shares of Isis Pharmaceuticals from an “underweight” rating to a “neutral” rating in a research note on Tuesday, November 26th. They now have a $38.00 price target on the stock, up previously from $25.00. One equities research analyst has rated the stock with a sell rating, five have given a hold rating and four have issued a buy rating to the stock. Isis Pharmaceuticals presently has a consensus rating of “Hold” and an average price target of $38.00.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.